Cambridge Investment Research Advisors, Inc. Verona Pharma PLC Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.6 Billion
- Q1 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Verona Pharma PLC stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 6,168 shares of VRNA stock, worth $649,490. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,168
Previous 4,699
31.26%
Holding current value
$649,490
Previous $218,000
79.82%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding VRNA
# of Institutions
294Shares Held
73.9MCall Options Held
933KPut Options Held
1.98M-
Perceptive Advisors LLC New York, NY6.56MShares$691 Million17.44% of portfolio
-
Janus Henderson Group PLC London, X05.52MShares$581 Million0.2% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y93.92MShares$413 Million17.31% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.46MShares$364 Million13.82% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.89MShares$305 Million3.9% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $6.42B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...